PL3400000T3 - Sposoby podawania angiotensyny ii - Google Patents
Sposoby podawania angiotensyny iiInfo
- Publication number
- PL3400000T3 PL3400000T3 PL17736407.2T PL17736407T PL3400000T3 PL 3400000 T3 PL3400000 T3 PL 3400000T3 PL 17736407 T PL17736407 T PL 17736407T PL 3400000 T3 PL3400000 T3 PL 3400000T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- administering angiotensin
- angiotensin
- administering
- Prior art date
Links
- 102000005862 Angiotensin II Human genes 0.000 title 1
- 101800000733 Angiotensin-2 Proteins 0.000 title 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title 1
- 229950006323 angiotensin ii Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
- G01N2410/02—Angiotensins; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276171P | 2016-01-07 | 2016-01-07 | |
US201662347292P | 2016-06-08 | 2016-06-08 | |
PCT/US2017/012485 WO2017120438A1 (en) | 2016-01-07 | 2017-01-06 | Methods for administering angiotensin ii |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3400000T3 true PL3400000T3 (pl) | 2024-04-22 |
Family
ID=59273945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17736407.2T PL3400000T3 (pl) | 2016-01-07 | 2017-01-06 | Sposoby podawania angiotensyny ii |
Country Status (11)
Country | Link |
---|---|
US (3) | US10406201B2 (pl) |
EP (1) | EP3400000B1 (pl) |
JP (1) | JP2019501201A (pl) |
KR (1) | KR20180108639A (pl) |
AU (2) | AU2017205168A1 (pl) |
BR (1) | BR112018013847A2 (pl) |
CA (1) | CA3010781A1 (pl) |
ES (1) | ES2973280T3 (pl) |
PL (1) | PL3400000T3 (pl) |
TW (1) | TW201733610A (pl) |
WO (1) | WO2017120438A1 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
US9220745B2 (en) | 2013-12-18 | 2015-12-29 | The George Washington University, a Congressionally Not-for-Profit Corporation | Angiotensin II alone or in combination for the treatment of hypotension |
US10406201B2 (en) | 2016-01-07 | 2019-09-10 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
WO2018191678A1 (en) | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
US5216025A (en) | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
CA2448051A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
WO2005044313A2 (en) | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
CN101316626A (zh) | 2005-09-29 | 2008-12-03 | 菲布罗根公司 | 用于降低血压的方法 |
AU2006332449B2 (en) | 2005-12-30 | 2008-05-15 | Howard Florey Institute Of Experimental Physiology And Medicine | A method of treatment |
WO2007146900A2 (en) * | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
AU2007321111A1 (en) | 2006-11-17 | 2008-05-22 | Da Volterra | Colonic delivery using Zn/pectin beads with a Eudragit coating. |
NZ606283A (en) | 2008-11-28 | 2014-08-29 | Abbvie Inc | Stable antibody compositions and methods for stabilizing same |
US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
KR20130026504A (ko) | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
EP3858437A1 (en) | 2013-04-26 | 2021-08-04 | La Jolla Pharma, LLC | Compositions and methods for treating renal failure |
US9220745B2 (en) | 2013-12-18 | 2015-12-29 | The George Washington University, a Congressionally Not-for-Profit Corporation | Angiotensin II alone or in combination for the treatment of hypotension |
US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
EP3381465A1 (en) | 2014-07-08 | 2018-10-03 | La Jolla Pharmaceutical Company | Methods for treating hypotension |
US10406201B2 (en) | 2016-01-07 | 2019-09-10 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
KR20180108630A (ko) | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 혈관수축제의 투여 방법 |
WO2018191678A1 (en) | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
US20190183962A1 (en) | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
-
2017
- 2017-01-06 US US15/400,275 patent/US10406201B2/en active Active
- 2017-01-06 TW TW106100418A patent/TW201733610A/zh unknown
- 2017-01-06 WO PCT/US2017/012485 patent/WO2017120438A1/en active Application Filing
- 2017-01-06 EP EP17736407.2A patent/EP3400000B1/en active Active
- 2017-01-06 BR BR112018013847A patent/BR112018013847A2/pt not_active Application Discontinuation
- 2017-01-06 ES ES17736407T patent/ES2973280T3/es active Active
- 2017-01-06 AU AU2017205168A patent/AU2017205168A1/en not_active Abandoned
- 2017-01-06 KR KR1020187022269A patent/KR20180108639A/ko not_active Application Discontinuation
- 2017-01-06 JP JP2018535412A patent/JP2019501201A/ja active Pending
- 2017-01-06 PL PL17736407.2T patent/PL3400000T3/pl unknown
- 2017-01-06 CA CA3010781A patent/CA3010781A1/en active Pending
-
2020
- 2020-03-26 US US16/831,182 patent/US20210030834A1/en not_active Abandoned
-
2021
- 2021-03-04 US US17/192,453 patent/US11219662B2/en active Active
-
2024
- 2024-02-19 AU AU2024201059A patent/AU2024201059A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210187058A1 (en) | 2021-06-24 |
ES2973280T3 (es) | 2024-06-19 |
WO2017120438A1 (en) | 2017-07-13 |
EP3400000A4 (en) | 2019-07-31 |
US20210030834A1 (en) | 2021-02-04 |
BR112018013847A2 (pt) | 2018-12-18 |
KR20180108639A (ko) | 2018-10-04 |
EP3400000B1 (en) | 2023-12-06 |
US20170224761A1 (en) | 2017-08-10 |
AU2017205168A1 (en) | 2018-08-16 |
JP2019501201A (ja) | 2019-01-17 |
US11219662B2 (en) | 2022-01-11 |
EP3400000A1 (en) | 2018-11-14 |
TW201733610A (zh) | 2017-10-01 |
CA3010781A1 (en) | 2017-07-13 |
US10406201B2 (en) | 2019-09-10 |
AU2024201059A1 (en) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256383A1 (zh) | 治療劑 | |
IL258931A (en) | Medicinal compounds and methods | |
GB201509893D0 (en) | Therapeutic agents | |
GB201517263D0 (en) | Therapeutic agents | |
GB201410816D0 (en) | Therapeutic agents | |
GB201415569D0 (en) | Therapeutic Compounds | |
HK1258727A1 (zh) | 治療性化合物 | |
GB201410216D0 (en) | Therapeutic | |
GB201509885D0 (en) | Therapeutic agents | |
GB201616839D0 (en) | Therapeutic compounds | |
GB201410815D0 (en) | Therapeutic agents | |
GB201410817D0 (en) | Therapeutic agents | |
PL3400000T3 (pl) | Sposoby podawania angiotensyny ii | |
GB201509888D0 (en) | Therapeutic agents | |
GB201416273D0 (en) | Therapeutic compounds | |
GB201415062D0 (en) | Therapeutic | |
GB201617339D0 (en) | Therapeutic compounds | |
GB201513299D0 (en) | Therapeutic agents | |
IL263821A (en) | Medicinal compounds | |
GB201521767D0 (en) | Therapeutic agents | |
GB2538767B (en) | Coffin | |
SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
GB201517264D0 (en) | Therapeutic agents | |
GB201609737D0 (en) | Therapeutic compounds | |
GB201609790D0 (en) | Therapeutic compounds |